2230-326x

Psoriasis Targets and Therapy

Dove Medical Press

View prefix report (10.2147)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 222 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact222 DOIs
2

Deposit reference lists for 98 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Medium impact98 DOIs
3

Attach ORCID iDs across 87 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact87 DOIs

DOIs for this ISSN

Showing the top 5 of 221 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Drug-induced psoriasis: clinical perspectives (10.2147/ptt.s126727)
Abstract References ORCID
149.67 98
2 Current knowledge on psoriasis and autoimmune diseases (10.2147/ptt.s64950)
Abstract References ORCID
149.01 96
3 Nail psoriasis: clinical features, pathogenesis, differentia… (10.2147/ptt.s126281)
Abstract References ORCID
143.14 80
4 Erythrodermic psoriasis: pathophysiology and current treatme… (10.2147/ptt.s101232)
Abstract References ORCID
132.81 58
5 Pustular psoriasis: pathophysiology and current treatment pe… (10.2147/ptt.s98954)
Abstract References ORCID
131.11 55
6 Psoriasis and smoking: links and risks (10.2147/ptt.s85189)
Abstract References ORCID
128.70 51
7 Tacrolimus for the management of psoriasis: clinical utility… (10.2147/ptt.s101233)
Abstract References ORCID
127.42 49
8 Targeting IL-23 in psoriasis: current perspectives (10.2147/ptt.s98893)
Abstract References ORCID
126.09 47
9 Fumaric acid esters in the management of psoriasis (10.2147/ptt.s51490)
Abstract References ORCID
120.15 39
10 Psoriasis and inflammatory bowel disease: links and risks (10.2147/ptt.s85194)
Abstract References ORCID
114.86 33
11 Type 2 diabetes and psoriasis: links and risks (10.2147/ptt.s159163)
Abstract References ORCID
111.85 30
12 <p>Psoriasis and alcohol</p> (10.2147/ptt.s164104)
Abstract References ORCID
110.78 29
13 Psoriasis in pregnancy: challenges and solutions (10.2147/ptt.s82975)
Abstract References ORCID
106.12 25
14 Psoriasis in children (10.2147/ptt.s87650)
Abstract References ORCID
102.13 22
15 Excimer laser for the treatment of psoriasis: safety, effica… (10.2147/ptt.s105047)
Abstract References ORCID
95.91 18
16 Combining biologic and phototherapy treatments for psoriasis… (10.2147/ptt.s98952)
Abstract References ORCID
88.21 14
17 The impact of genital psoriasis on quality of life: a system… (10.2147/ptt.s169389)
Abstract References
88.17 57
18 Management of scalp psoriasis: current perspectives (10.2147/ptt.s85330)
Abstract References ORCID
85.96 13
19 Assessing and Improving Psychological Well-Being in Psoriasi… (10.2147/ptt.s328447)
Abstract ORCID
85.80 51
20 Local effects of adipose tissue in psoriasis and psoriatic a… (10.2147/ptt.s122959)
Abstract References ORCID
83.55 12
21 <p>Diagnosis and screening of patients with generalize… (10.2147/ptt.s181808)
Abstract References
82.66 44
22 <p>Acrodermatitis continua of Hallopeau: clinical pers… (10.2147/ptt.s180608)
Abstract References
81.16 41
23 Role of mesenchymal stem cells in the pathogenesis of psoria… (10.2147/ptt.s108311)
Abstract References ORCID
78.10 10
24 Spotlight on risankizumab and its potential in the treatment… (10.2147/ptt.s165943)
Abstract References ORCID
78.10 10
25 Monitoring methotrexate-induced liver fibrosis in patients w… (10.2147/ptt.s141629)
Abstract References
77.82 35
26 Updates on the Treatment of Erythrodermic Psoriasis (10.2147/ptt.s288345)
Abstract ORCID
77.20 34
27 The metabolomics of psoriatic disease (10.2147/ptt.s118348)
Abstract References
75.26 31
28 Calcipotriol/betamethasone for the treatment of psoriasis: e… (10.2147/ptt.s63127)
Abstract References ORCID
75.00 9
29 <p>Psoriasis and uveitis: links and risks</p> (10.2147/ptt.s179182)
Abstract References
73.86 29
30 Biologics in Psoriasis: Updated Perspectives on Long-Term Sa… (10.2147/ptt.s328575)
Abstract ORCID
73.86 29
31 Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with P… (10.2147/ptt.s342911)
Abstract ORCID
73.86 29
32 Psoriasis and sexual dysfunction: links, risks, and manageme… (10.2147/ptt.s159916)
Abstract References
72.36 27
33 Monitoring treatment response in psoriasis: current perspect… (10.2147/ptt.s107514)
Abstract References ORCID
71.57 8
34 Psoriasis: epidemiology, natural history, and differential d… (10.2147/ptt.s24009)
Abstract References ORCID
71.57 8
35 Biologics Can Significantly Improve Dermatology Life Quality… (10.2147/ptt.s356568)
Abstract ORCID
70.75 25
36 <p>A narrative review of psoriasis and multiple sclero… (10.2147/ptt.s186637)
Abstract References
69.01 23
37 Evaluation of ADA activity as a potential marker of disease… (10.2147/ptt.s174119)
Abstract References ORCID
67.73 7
38 The management of psoriasis through diet (10.2147/ptt.s24755)
Abstract References ORCID
67.73 7
39 Links and risks associated with psoriasis and metabolic synd… (10.2147/ptt.s54089)
Abstract References ORCID
67.73 7
40 Secukinumab in the treatment of psoriasis: patient selection… (10.2147/ptt.s146004)
Abstract References
65.05 19
41 The Physician Global Assessment and Body Surface Area compos… (10.2147/ptt.s169333)
Abstract References
65.05 19
42 <p>Increased dermal expression of chromatin-associated… (10.2147/ptt.s190507)
Abstract References
65.05 19
43 Challenges Psoriasis and Its Impact on Quality of Life: Chal… (10.2147/ptt.s519420)
Abstract References
65.05 19
44 Psoriasis patients’ experiences concerning medical… (10.2147/ptt.s109557)
Abstract References ORCID
63.38 6
45 Epidemiology and treatment of psoriasis: a Brazilian perspec… (10.2147/ptt.s51725)
Abstract References ORCID
63.38 6
46 Improving patient outcomes in psoriasis: strategies to ensur… (10.2147/ptt.s54070)
Abstract References ORCID
63.38 6
47 Real-World Experience of Bimekizumab in a Cohort of 109 Pati… (10.2147/ptt.s514249)
Abstract References
62.76 17
48 <p>Tofacitinib in the management of active psoriatic a… (10.2147/ptt.s161453)
Abstract References
58.80 14
49 Herpes zoster in psoriasis patients undergoing treatment wit… (10.2147/ptt.s102202)
Abstract References ORCID
58.36 5
50 Epidemiology and treatment of psoriasis: a Chinese perspecti… (10.2147/ptt.s51717)
Abstract References ORCID
58.36 5